SCHEMBL3606948

SCHEMBL3606948

N=C(N)Nc1nc(-c2cccc(N3C(=O)c4ccccc4C3=O)c2)cs1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.61
MEN1 O00255 7/20 0.61
MAPT P10636 6/20 0.61
ALDH1A1 P00352 4/20 0.59
TDP1 Q9NUW8 1/20 0.59
GAA P10253 3/20 0.59
TP53 P04637 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
POLB P06746 1/20 0.59
PKM P14618 1/20 0.59
AR P10275 1/20 0.45
ABL1 P00519 2/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TRPA1 O75762 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL11244349 0.99 KMT2A (0.62) KMT2AMEN1MAPTALDH1A1TDP1
Bromide SCHEMBL11243390 0.85 KMT2A (0.62) KMT2AMEN1MAPTALDH1A1TDP1
Bromide SCHEMBL11243391 0.85 KMT2A (0.62) KMT2AMEN1MAPTALDH1A1TDP1
SCHEMBL3605905 0.82 KMT2A (0.53) KMT2AMEN1MAPTABL1RAB9A
Hydrochloric Acid SCHEMBL11253214 0.81 KMT2A (0.52) KMT2AMEN1MAPTABL1RAB9A
Bromide SCHEMBL11247477 0.79 KMT2A (0.59) KMT2AMEN1MAPTALDH1A1TDP1
Bromide SCHEMBL11247478 0.79 KMT2A (0.59) KMT2AMEN1MAPTALDH1A1TDP1
SCHEMBL3615155 0.79 ALOX5 (0.51) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL3603436 0.77 MEN1 (0.61) KMT2AMEN1MAPTALDH1A1GAA
SCHEMBL3603750 0.77 MAPT (0.55) KMT2AMEN1MAPTALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US claimed
CN-101466692-A Thiazol-guanidine derivatives useful as a (beta) - related pathologies ASTRAZENECA AB (SE) 2009-06-24 CN claimed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
CN-101466692-A Thiazol-guanidine derivatives useful as a (beta) - related pathologies ASTRAZENECA AB (SE) 2009-06-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 KMT2A 4116/4885MEN1 3257/4885MAPT 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.